Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 4,779 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Cancers Clear all

Conditions: Multiple Myeloma
Interventions: CC-4047; Drug
Lead sponsor: Celgene; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Summit, New Jersey

Conditions: High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions: Linvoseltamab, Daratumumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 9
States / cities: Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Positron-Emission Tomography, Metastatic Solid Tumors
Interventions: ⁸⁹Zr-Df-IAB22M2C; Drug
Lead sponsor: ImaginAb, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more

Conditions: Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Diseases
Interventions: AGS-16M18; Biological
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Image, Warburg Effect, Tumors
Interventions: Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer
Interventions: AMMA Portalbe Scalp Cooling System; Device
Lead sponsor: Cooler Heads Care Inc.; Government
Eligibility: 21 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Tucson, Arizona • Urbana, Illinois

Conditions: Advanced Solid Tumors
Interventions: intravenous (IV) infusion; Drug
Lead sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more

Conditions: Autologous Hematopoietic Stem Cell Transplant
Interventions: RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: ODM-201; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Wheat Ridge, Colorado • Norwich, Connecticut • Ocala, Florida + 5 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Anakinra (IL-1Ra), Dexamethasone acetate; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Amyloidosis; Systemic
Interventions: AT-02, AT-02 (Placebo); Drug · Other
Lead sponsor: Attralus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Overland Park, Kansas • Baltimore, Maryland • Kansas City, Missouri + 3 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interferon alfa, recombinant interleukin-12; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Pembrolizumab, SAR444245 (Thor-707), Cetuximab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Duarte, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more

Conditions: Multiple Myeloma
Interventions: bortezomib, dexamethasone, thalidomide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 127
States / cities: Little Rock, Arkansas • Alton, Illinois • Mount Vernon, Illinois + 80 more

Conditions: Hepatocellular Carcinoma
Interventions: GC33(RO5137382), Sorafenib; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 5
States / cities: San Francisco, California • Miami, Florida • New York, New York + 2 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan; Drug · Procedure
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Bone Metastases, Multiple Myeloma
Interventions: ExAblate MRfFUS, Sham; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more

Conditions: Solid Tumors, Lymphoma
Interventions: Alisertib, Esomeprazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more

Conditions: Breast Cancer
Interventions: pharmacodynamic analysis; Drug
Lead sponsor: National Institute of General Medical Sciences (NIGMS); NIH
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Multiple Myeloma
Interventions: Lenalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphocytic Leukemia, Chronic
Interventions: obinutuzumab, rituximab, chlorambucil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Ovarian Neoplasms
Interventions: AMG 479, AMG 479 Placebo; Drug
Lead sponsor: Translational Research in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 23
States / cities: Alhambra, California • Burbank, California • Fullerton, California + 17 more

Conditions: Hippel-Lindau Disease, Kidney Cancer
Interventions: 17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: AML, Adult Recurrent, MDS
Interventions: LYT-200, Venetoclax, Azacitidine, Decitabine; Drug
Lead sponsor: PureTech; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 6 more

Search by objective public record fields.

Expanded Access for CC-4047

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

HP Pyruvate MRI in Cancers

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

Muscle Stimulation for Physical Function During Stem Cell Transplant

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Aromatase Inhibitor Clinical Trial

Lenalidomide Maintenance Therapy for Multiple Myeloma

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)